Trials / Recruiting
RecruitingNCT05140148
Promoting Recovery After STroke With Amantadine
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The investigators aim to examine whether amantadine can help patients recover from stroke. This will be a blinded randomized clinical trial (RCT). Patients will be randomized post-ischemic or hemorrhagic stroke either to the placebo arm or amantadine arm. Patients will be on study drug or placebo for 1 month but will be enrolled for 3 months total. At various time points patients will be examined and fill out questionnaires to determine level of stroke recovery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amantadine | Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease |
| DRUG | Placebo | placebo pills |
Timeline
- Start date
- 2022-02-01
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
- First posted
- 2021-12-01
- Last updated
- 2026-03-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05140148. Inclusion in this directory is not an endorsement.